SNY vs AZN

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus 5. 5% for Sanofi (SNY). Sanofi (SNY) offers the better valuation at 18. 4x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate Sanofi (SNY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sanofi (SNY) is the cheapest at 18.

4x versus AstraZeneca PLC at 28. 3x. On forward P/E, Sanofi is actually cheaper at 10. 4x.

Over the past 5 years, AstraZeneca PLC (AZN) delivered a total return of +87.

0%, compared to +5. 3% for Sanofi (SNY). Over 10 years, the gap is even starker: AZN returned +290. 3% versus SNY's +60. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sanofi (SNY) is the lower-risk stock at 0.

51β versus AstraZeneca PLC's 0. 67β — meaning AZN is approximately 30% more volatile than SNY relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 61% for AstraZeneca PLC — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus 5. 5% for Sanofi (SNY). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -7. 3% for Sanofi. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AstraZeneca PLC (AZN) is the more profitable company, earning 17.

5% net margin versus 16. 7% for Sanofi — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZN leads at 23. 4% versus 13. 6% for SNY. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sanofi (SNY) trades at 10.

4x forward P/E versus 18. 0x for AstraZeneca PLC — 7. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 14. 2% to $50. 00.

All stocks in this comparison pay dividends.

Sanofi (SNY) offers the highest yield at 5. 0%, versus 1. 8% for AstraZeneca PLC (AZN).

For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

67), 1. 8% yield, +290. 3% 10Y return). Both have compounded well over 10 years (AZN: +290. 3%, SNY: +60. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNY is a mid-cap income-oriented stock; AZN is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.